- 专利标题： Biomarkers, test method, and test kit for predicting therapeutic effect of anti-VEGFR-2 antibody drug
-
申请号： US16473712申请日： 2017-12-27
-
公开(公告)号： US11415584B2公开(公告)日： 2022-08-16
- 发明人: Tetsuo Mashima , Takeru Wakatsuki , Hiroyuki Seimiya , Kensei Yamaguchi
- 申请人： JAPANESE FOUNDATION FOR CANCER RESEARCH
- 申请人地址： JP Tokyo
- 专利权人： JAPANESE FOUNDATION FOR CANCER RESEARCH
- 当前专利权人： JAPANESE FOUNDATION FOR CANCER RESEARCH
- 当前专利权人地址： JP Tokyo
- 代理机构： Rankin, Hill & Clark LLP
- 优先权： JPJP2016-255887 20161228
- 国际申请： PCT/JP2017/046831 WO 20171227
- 国际公布： WO2018/124153 WO 20180705
- 主分类号： G01N33/68
- IPC分类号： G01N33/68
摘要：
The therapeutic effect of and/or prognosis after administration of an anti-VEGFR-2 antibody drug, in particular, ramucirumab can be predicted by measuring VEGF-A, VEGF-D, sVEGFR-2, SDF-1α, and/or cNRP1. Provided is a biomarker for predicting the effect of administration of the anti-VEGFR-2 antibody drug, in particular, ramucirumab, and a test method and a test kit using the marker.
信息查询
IPC分类:
